CO2022011388A2 - Inhibidores heterocíclicos de pad4 - Google Patents
Inhibidores heterocíclicos de pad4Info
- Publication number
- CO2022011388A2 CO2022011388A2 CONC2022/0011388A CO2022011388A CO2022011388A2 CO 2022011388 A2 CO2022011388 A2 CO 2022011388A2 CO 2022011388 A CO2022011388 A CO 2022011388A CO 2022011388 A2 CO2022011388 A2 CO 2022011388A2
- Authority
- CO
- Colombia
- Prior art keywords
- pad4
- compounds
- heterocyclic
- pad4 inhibitors
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 abstract 2
- 101150094373 Padi4 gene Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000001420 substituted heterocyclic compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Luminescent Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041006146 | 2020-02-12 | ||
| PCT/US2021/017554 WO2021163254A1 (en) | 2020-02-12 | 2021-02-11 | Heterocyclic pad4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022011388A2 true CO2022011388A2 (es) | 2022-08-30 |
Family
ID=74856949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0011388A CO2022011388A2 (es) | 2020-02-12 | 2022-08-12 | Inhibidores heterocíclicos de pad4 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12473304B2 (https=) |
| EP (1) | EP4103559B1 (https=) |
| JP (1) | JP7711075B2 (https=) |
| KR (1) | KR20220140795A (https=) |
| CN (1) | CN115348961B (https=) |
| AR (1) | AR121299A1 (https=) |
| AU (1) | AU2021219710A1 (https=) |
| BR (1) | BR112022015792A2 (https=) |
| CA (1) | CA3167753A1 (https=) |
| CL (1) | CL2022002148A1 (https=) |
| CO (1) | CO2022011388A2 (https=) |
| IL (1) | IL295506A (https=) |
| MX (1) | MX2022009874A (https=) |
| PE (1) | PE20230679A1 (https=) |
| TW (1) | TW202140477A (https=) |
| WO (1) | WO2021163254A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2021158840A1 (en) | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Macrocyclic pad4 inhibitors useful as immunosuppressant |
| TW202140477A (zh) | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環ｐａｄ４抑制劑 |
| WO2021222353A1 (en) | 2020-04-30 | 2021-11-04 | Gilead Sciences, Inc. | Macrocyclic inhibitors of peptidylarginine deiminases |
| TW202233174A (zh) | 2020-12-22 | 2022-09-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
| WO2022140390A1 (en) | 2020-12-22 | 2022-06-30 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
| KR20260041867A (ko) | 2023-07-21 | 2026-03-27 | 브리스톨-마이어스 스큅 컴퍼니 | Pad4 조정제의 시트룰린화 및 활성을 평가하는 방법 |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60007310D1 (de) | 1999-06-04 | 2004-01-29 | Elan Pharma Int Ltd | Zusammensetzungen und methoden zur verhinderung des zelltods |
| MX2007010371A (es) | 2005-02-25 | 2008-01-11 | Tetralogic Pharmaceuticals | Inhibidores dimericos iap. |
| US7825154B2 (en) | 2005-08-12 | 2010-11-02 | The United States Of America As Represented By The Secretary Of The Army | Small molecule inhibitors of botulinum neurotoxins |
| CN101466670B (zh) | 2006-04-07 | 2013-04-17 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| US7842713B2 (en) | 2006-04-20 | 2010-11-30 | Pfizer Inc | Fused phenyl amido heterocyclic compounds |
| EP2120952A4 (en) | 2007-01-15 | 2011-09-21 | Us Of America As Represented By The Secretary Of The Army On Behalf Of The U S Army Res Inst Of Infe | ANTIVIRAL COMPOUNDS AND METHODS OF USE |
| US20110052562A1 (en) | 2007-12-19 | 2011-03-03 | The Scripps Research Institute | Benzimidazoles and analogs as rho kinase inhibitors |
| JP2010013386A (ja) | 2008-07-02 | 2010-01-21 | Fujifilm Corp | 染毛剤、染毛方法およびその製造方法 |
| WO2013040528A1 (en) | 2011-09-16 | 2013-03-21 | Microbiotix, Inc. | Antimicrobial compounds |
| WO2013052263A2 (en) | 2011-09-16 | 2013-04-11 | Microbiotix, Inc. | Antifungal compounds |
| KR101916443B1 (ko) * | 2012-07-26 | 2018-11-08 | 글락소 그룹 리미티드 | Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸 |
| CN103030627B (zh) | 2013-01-07 | 2017-11-10 | 中国科学院上海有机化学研究所 | 一种噻吩环/呋喃环‑杂芳环结构的合成方法 |
| WO2014177593A1 (en) | 2013-04-29 | 2014-11-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Amorfrutin analogs as ppargamma-modulators |
| WO2016004513A1 (en) | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| KR101501091B1 (ko) | 2014-09-04 | 2015-03-10 | 주식회사 해치엠엠에이 | 도포용 바닥재의 미끄럼방지 요철형성용 롤러장치 |
| KR20180005250A (ko) * | 2015-05-21 | 2018-01-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Pad4 억제제로서의 벤조이미다졸 유도체 |
| US20180312493A1 (en) | 2015-11-04 | 2018-11-01 | Simon Fraser University | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor |
| AR107032A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| AR107030A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
| US10654814B2 (en) * | 2015-12-22 | 2020-05-19 | Kancera Ab | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity |
| CA3015482A1 (en) | 2016-02-23 | 2017-08-31 | Padlock Therapeutics, Inc. | Heteroaryl inhibitors of pad4 |
| WO2018022897A1 (en) | 2016-07-27 | 2018-02-01 | Padlock Therapeutics, Inc. | Covalent inhibitors of pad4 |
| US11026937B2 (en) | 2016-09-12 | 2021-06-08 | Padlock Therapeutics, Inc. | Heteroaryl inhibitors of PAD4 |
| JP2018140974A (ja) | 2017-02-28 | 2018-09-13 | 国立大学法人 奈良先端科学技術大学院大学 | 放射線検出方法及び放射線検出器並びに放射線検出に用いられる新規化合物 |
| CN108689942B (zh) | 2017-04-11 | 2023-06-09 | 广东东阳光药业有限公司 | 含氮双环化合物及其制备方法和用途 |
| JP7311228B2 (ja) * | 2017-06-30 | 2023-07-19 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 |
| ES2932627T3 (es) | 2017-08-22 | 2023-01-23 | Bayer Ag | Derivados heterocíclicos como pesticidas |
| AU2018352142B2 (en) * | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| MX2021001565A (es) | 2018-08-08 | 2021-04-19 | Bristol Myers Squibb Co | Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad). |
| MX2021001471A (es) | 2018-08-08 | 2021-04-28 | Bristol Myers Squibb Co | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). |
| JP7447080B2 (ja) | 2018-08-08 | 2024-03-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐａｄ４阻害剤としての置換チエノピロール |
| US20220348562A1 (en) | 2018-08-08 | 2022-11-03 | Bristol-Myers Squibb Company | Benzimidazole inhibitors of pad enzymes |
| WO2021158840A1 (en) | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Macrocyclic pad4 inhibitors useful as immunosuppressant |
| TW202140477A (zh) | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環ｐａｄ４抑制劑 |
-
2021
- 2021-02-09 TW TW110105125A patent/TW202140477A/zh unknown
- 2021-02-10 AR ARP210100336A patent/AR121299A1/es not_active Application Discontinuation
- 2021-02-11 US US17/799,028 patent/US12473304B2/en active Active
- 2021-02-11 CN CN202180025726.9A patent/CN115348961B/zh active Active
- 2021-02-11 MX MX2022009874A patent/MX2022009874A/es unknown
- 2021-02-11 CA CA3167753A patent/CA3167753A1/en active Pending
- 2021-02-11 IL IL295506A patent/IL295506A/en unknown
- 2021-02-11 EP EP21709851.6A patent/EP4103559B1/en active Active
- 2021-02-11 PE PE2022001712A patent/PE20230679A1/es unknown
- 2021-02-11 BR BR112022015792A patent/BR112022015792A2/pt not_active Application Discontinuation
- 2021-02-11 KR KR1020227031398A patent/KR20220140795A/ko active Pending
- 2021-02-11 AU AU2021219710A patent/AU2021219710A1/en not_active Abandoned
- 2021-02-11 JP JP2022548707A patent/JP7711075B2/ja active Active
- 2021-02-11 WO PCT/US2021/017554 patent/WO2021163254A1/en not_active Ceased
-
2022
- 2022-08-10 CL CL2022002148A patent/CL2022002148A1/es unknown
- 2022-08-12 CO CONC2022/0011388A patent/CO2022011388A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021219710A1 (en) | 2022-10-06 |
| US12473304B2 (en) | 2025-11-18 |
| EP4103559B1 (en) | 2026-03-04 |
| JP2023515780A (ja) | 2023-04-14 |
| US20230167131A1 (en) | 2023-06-01 |
| AR121299A1 (es) | 2022-05-04 |
| KR20220140795A (ko) | 2022-10-18 |
| EP4103559A1 (en) | 2022-12-21 |
| PE20230679A1 (es) | 2023-04-21 |
| CN115348961B (zh) | 2025-03-04 |
| CA3167753A1 (en) | 2021-08-19 |
| JP7711075B2 (ja) | 2025-07-22 |
| TW202140477A (zh) | 2021-11-01 |
| MX2022009874A (es) | 2022-08-22 |
| BR112022015792A2 (pt) | 2022-10-11 |
| WO2021163254A1 (en) | 2021-08-19 |
| IL295506A (en) | 2022-10-01 |
| CN115348961A (zh) | 2022-11-15 |
| CL2022002148A1 (es) | 2023-02-24 |
| EP4103559C0 (en) | 2026-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022011388A2 (es) | Inhibidores heterocíclicos de pad4 | |
| CL2021001991A1 (es) | Compuestos 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria cdk2. | |
| DOP2025000264A (es) | Inhibidores de kras de 2-azabiciclo [2.2.1] heptano | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2022018811A2 (es) | Inhibidores de la proteína kras g12c y usos de estos | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| CO2018010966A2 (es) | Nuevos derivados de pirazolopirimidina | |
| BR112017024331A2 (pt) | composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto | |
| CL2019000986A1 (es) | 1,3 di sustituto ciclobutano o derivados de azetidina como inhibidores de prostaglandina d sintasa hematopoyética(h-pgds). | |
| NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
| GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
| UY33476A (es) | Estimuladores de sgc | |
| NI201100081A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes. | |
| SV2011003853A (es) | Compuestos organicos | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| CO2023001668A2 (es) | Derivados de 1h-benzo[d]imidazol como inhibidores de tlr9 para el tratamiento de fibrosis | |
| BR112014019622B8 (pt) | composto, seus usos, composição pesticida, material de propagação de plantas tratado e composições farmacêuticas | |
| BR112022001054A2 (pt) | Inibidores enzimáticos | |
| UY39517A (es) | Inhibidores de la btk | |
| BR112023015721A2 (pt) | Derivados tricíclicos úteis como inibidores de parp7 | |
| BR112022022452A2 (pt) | Inibidores de il4i1 e métodos de uso | |
| MX2023012851A (es) | Métodos de tratamiento y seguimiento de la enfermedad de parkinson. | |
| AR076263A1 (es) | Composiciones y metodos para tratar cancer. uso. | |
| MX2023000164A (es) | Métodos y composiciones para tratar la hemofilia. | |
| UY39434A (es) | Nuevos compuestos |